Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes.

ABSTRACT:

Aim

Cetuximab is a standard-of-care treatment for KRAS wild-type metastatic colorectal cancer (mCRC), but it may also be effective in a subgroup of KRAS mutant patients by its immunomodulatory activity. Here, we explore if KIR (killer cell immunoglobulin-like receptor) genotyping can provide a significant added value in the clinical outcome of patients with KRAS mutant mCRC based on cetuximab treatment.

Methods

We included 69 patients with histologically confirmed mCRC and KRAS mutation, positive EGFR expression, and Eastern Cooperative Oncology Group performance status ≤2. Based on KIR gene content, haplotype (A or B) was defined and genotypes (AA or Bx) were grouped for each patient.

Results

We demonstrated with new evidence the immunomod

SUBMITTER: Manzanares-Martin B 

PROVIDER: S-EPMC8039212 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature